348 related articles for article (PubMed ID: 26223602)
1. Antibody drugs for Alzheimer's show glimmers of promise.
Reardon S
Nature; 2015 Jul; 523(7562):509-10. PubMed ID: 26223602
[No Abstract] [Full Text] [Related]
2. Alzheimer's drugs take a new tack.
Callaway E
Nature; 2012 Sep; 489(7414):13-4. PubMed ID: 22962697
[No Abstract] [Full Text] [Related]
3. Amyloid Cascade into Clarity.
Weitz TM; Town T
Immunity; 2016 Oct; 45(4):717-718. PubMed ID: 27760336
[TBL] [Abstract][Full Text] [Related]
4. Novel strategies for Alzheimer's disease treatment: An overview of anti-amyloid beta monoclonal antibodies.
Rygiel K
Indian J Pharmacol; 2016; 48(6):629-636. PubMed ID: 28066098
[TBL] [Abstract][Full Text] [Related]
5. Structural aspects of Alzheimer's disease immunotherapy targeted against amyloid-beta peptide.
Cehlar O; Skrabana R; Revajova V; Novak M
Bratisl Lek Listy; 2018; 119(4):201-204. PubMed ID: 29663816
[TBL] [Abstract][Full Text] [Related]
6. [Immunotherapy for Alzheimer's disease].
Falkentoft AC; Hasselbalch SG
Ugeskr Laeger; 2016 Jan; 178(3):V07150588. PubMed ID: 26815584
[TBL] [Abstract][Full Text] [Related]
7. NEUROSCIENCE. Alzheimer's amyloid theory gets modest boost.
Underwood E
Science; 2015 Jul; 349(6247):464. PubMed ID: 26228122
[No Abstract] [Full Text] [Related]
8. Drugs: a tangled web of targets.
Gravitz L
Nature; 2011 Jul; 475(7355):S9-11. PubMed ID: 21760583
[No Abstract] [Full Text] [Related]
9. Alzheimer disease: Anti-Aβ antibody treatment shows promise in Alzheimer disease.
Fyfe I
Nat Rev Neurol; 2016 Oct; 12(10):554-5. PubMed ID: 27632905
[No Abstract] [Full Text] [Related]
10. Genentech's Alzheimer's antibody trial to study disease prevention.
Garber K
Nat Biotechnol; 2012 Aug; 30(8):731-2. PubMed ID: 22871696
[No Abstract] [Full Text] [Related]
11. Bapineuzumab in Alzheimer's disease: where now?
Wilcock GK
Lancet Neurol; 2010 Feb; 9(2):134-6. PubMed ID: 20129159
[No Abstract] [Full Text] [Related]
12. Amyloid beta peptide immunotherapy in Alzheimer disease.
Delrieu J; Ousset PJ; Voisin T; Vellas B
Rev Neurol (Paris); 2014 Dec; 170(12):739-48. PubMed ID: 25459121
[TBL] [Abstract][Full Text] [Related]
13. Investigational drugs in Alzheimer's disease: current progress.
Berk C; Paul G; Sabbagh M
Expert Opin Investig Drugs; 2014 Jun; 23(6):837-46. PubMed ID: 24702504
[TBL] [Abstract][Full Text] [Related]
14. Solanezumab and the amyloid hypothesis for Alzheimer's disease.
Le Couteur DG; Hunter S; Brayne C
BMJ; 2016 Dec; 355():i6771. PubMed ID: 28034844
[No Abstract] [Full Text] [Related]
15. The search for Alzheimer disease therapeutics - same targets, better trials?
Rafii MS; Aisen PS
Nat Rev Neurol; 2020 Nov; 16(11):597-598. PubMed ID: 32963375
[No Abstract] [Full Text] [Related]
16. Biogen's aducanumab raises hope that Alzheimer's can be treated at its source.
Patel KR
Manag Care; 2015 Jun; 24(6):19. PubMed ID: 26182718
[No Abstract] [Full Text] [Related]
17. Alzheimer's drug update. Harvard researchers help test new drugs that could strike at the root of Alzheimer's disease. Here's where things stand.
Harv Mens Health Watch; 2013 Jan; 17(6):6-7. PubMed ID: 23819191
[No Abstract] [Full Text] [Related]
18. Alzheimer's drug donanemab helps most when taken at earliest disease stage, study finds.
Reardon S
Nature; 2023 Jul; 619(7971):682-683. PubMed ID: 37460689
[No Abstract] [Full Text] [Related]
19. Amyloid-beta (Aβ)-targeting monoclonal antibody trials in early Alzheimer's disease-Clinical outcome with gantenerumab.
Xiao B; Tan EK
Clin Transl Med; 2024 Jan; 14(1):e1559. PubMed ID: 38279873
[No Abstract] [Full Text] [Related]
20. Failed Alzheimer's trial does not kill leading theory of disease.
Abbott A; Dolgin E
Nature; 2016 Nov; 540(7631):15-16. PubMed ID: 27905452
[No Abstract] [Full Text] [Related]
[Next] [New Search]
